Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were ...

Eric Le Berrigaud, an analyst from Stifel Nicolaus, maintained the Buy rating on Sanofi (SNYNF – Research Report). The associated price target ...

If you're considering getting Starlink satellite internet, check out this simplified breakdown of the different pricing tiers, subscription costs, and equipment fees. My title is Senior Features ...

Netflix is starting off the new year with another subscription price hike. The latest price change, Netflix's first in the U.S. since October 2023, comes after the company reported adding a record ...

“So we’re going to roll up our sleeves.” He also said that work on reducing out-of-pocket drug costs and reforming the role of pharmacy benefit managers’ in drug pricing will continue with the new ...

WASHINGTON, Jan 20 (Reuters) - U.S. President Donald Trump on Monday called on federal government agencies to take action aimed at lowering American consumer costs, but gave no other details ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

Here he is earlier today: The Switch 2 is unlikely to be priced any lower than $349, the current cost of an OLED Switch model. $399 seems like a safe bet — the same price as the base Steam Deck.